Provided is a practical microneedle preparation which solves the problem that even if it is possible for a drug to be applied quantitatively onto a tip end portion of a microneedle, a drug residue isgenerated on the stratum corneum when the drug is actually used as a percutaneous absorption medication. In a microneedle array in which a needle length is at least equal to 350 [mu]m and at most equal to 900 [mu]m, the diameter of the apex of the needle tip end portion is at least equal to 20 [mu]m and at most equal to 100 [mu]m, which has a drug coat coating portion, and which has a bio-insoluble polymer as a base, a lower edge of the drug coating portion is at least 200 [mu]m from a root of the needle.